Fields
Immunotherapy Research
Immunotherapy research investigates how to harness, augment, or redirect the immune system to treat diseases—particularly cancer, but also autoimmune disorders, infectious diseases, and transplant rejection. The field has been transformed by two landmark advances: immune checkpoint inhibitors that block CTLA-4, PD-1, or PD-L1 to unleash anti-tumor T cells, and CAR-T cell therapy using engineered T cells expressing chimeric antigen receptors that recognize tumor surface markers. Checkpoint immunotherapy now forms a cornerstone of treatment for melanoma, lung cancer, and many other tumor types; CAR-T therapies have achieved remarkable remissions in blood cancers previously considered untreatable. Beyond oncology, mRNA vaccine platforms validated by COVID-19 vaccines are being retooled for personalized cancer vaccines encoding tumor neoantigens specific to each patient's mutational landscape. Research frontiers include understanding why some patients respond while others do not and overcoming immunosuppressive tumor microenvironments in solid tumors.
Details
- Avg Funding
- $2,100,000 per year
- Key Technologies
- CAR Construct Lentiviral VectorsImmune Checkpoint Antibody EngineeringmRNA Vaccine PlatformsSingle-Cell TCR and BCR SequencingTumor-Infiltrating Lymphocyte Expansion
- Subfields
- CAR-T Cell TherapyCheckpoint ImmunotherapyCancer VaccinesImmunomodulatory BiologicsInnate Immune Modulation
- Top Institutions
- Memorial Sloan Kettering Cancer CenterMD Anderson Cancer CenterUniversity of PennsylvaniaNCI National Cancer InstituteFrancis Crick Institute